Table 3: Antioxidant activity changesa of released caffeic acid from nanocarriers in gastric and intestinal simulated condition.

TreatmentDPPH assay (%) Reducing activity
( g/mL of caffeic acid)
Gastric mediaIntestine mediaGastric mediaIntestine media

T15.85 ± 1.348.39 ± 2.5612.44 ± 0.614.7 ± 0.34
T20.000.19 ± 0.095.3 ± 0.191.23 ± 0.10
T39.16 ± 1.043.7 ± 0.619.36 ± 1.070.96 ± 0.05
T40.002.15 ± 0.8821.48 ± 0.110.38 ± 0.33
T511.24 ± 0.217.8 ± 1.865.6 ± 0.932.3 ± 1.28
T615.6 ± 3.370.000.27 ± 0.10.83 ± 0.23
T73.07 ± 0.233.2 ± 0.734.78 ± 1.163.84 ± 0.68

T1: caffeic acid released from solid lipid nanoparticles.
T2: caffeic acid released from solid lipid nanoparticles coated with 0.1% PEC-CH.
T3: caffeic acid released from solid lipid nanoparticles coated with 0.25% PEC-CH.
T4: caffeic acid released from solid lipid nanoparticles coated with 0.5% PEC-CH.
T5: caffeic acid released from solid lipid nanoparticles coated with 0.1% AL-CH.
T6: caffeic acid released from solid lipid nanoparticles coated with 0.25% AL-CH.
T7: caffeic acid released from solid lipid nanoparticles coated with 0.5% AL-CH.
aResults are expressed as the means of three replications ± standard error of mean.